AbbVie has been accused of exploiting the country’s patent system to drive up prices for its rheumatoid arthritis drug Humira and cancer drug Imbruvica by the U.S. House Committee on Oversight and ...

Since its spin-off from Abbott Labs, AbbVie has delivered outstanding performance, surpassing both its parent company and the S&P 500, thanks to the success of Humira. In 2022, AbbVie became the ...

A federal judge ruled that AbbVie didn’t break antitrust laws by settling patent lawsuits regarding its blockbuster rheumatoid arthritis drug, Humira, STAT reported. A class-action lawsuit was filed ...

AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth. The company has a solid track record of increasing dividends and offers an attractive current ...

AbbVie is treading water with sales as Humira fades. But it could mean several years without meaningful earnings growth. There are long-term opportunities, but don't rush to buy the stock. The company ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of biosimilar competition, polling doctors about forces shaping the market and their ...

Dividend stocks can provide a meaningful path to enhancing your portfolio returns. Investing in businesses with a track record of profitability and favorable cash flows that have the financial ...

Humira has been one of the world's top selling drugs for more than two decades. But thanks to some new copycats — including one that is being sold at entrepreneur Mark Cuban's online pharmacy — its ...

Over 60% of AbbVie Inc.’s (NYSE: ABBV) sales come from demand for Humira -- an autoimmune-disease drug prescribed to patients with a variety of conditions -- that racks up sales of $16 billion per ...

(Reuters) - Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira.